Bafna Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE878I01022
NSEID: BAFNAPH
BSEID: 532989
View on NSE | View on BSE

INR

154.80

7.35 (4.98%)

BSENSE

Jun 03, 03:30 PM

BSE+NSE Vol: 6.18 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Ambalal Sarabhai

Medico Remedies

Medicamen Biotec

Trident Lifeline

Bafna Pharma.

Albert David

Valiant Laborato

Aptus Pharma

Transchem

Astonea Labs

Infinium Pharma

Why is Bafna Pharmaceuticals Ltd ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.26%

Poor long term growth as Operating profit has grown by an annual rate 11.18% of over the last 5 years

Flat results in Mar 26

NON-OPERATING INCOME(Q) is 67.18 % of Profit Before Tax (PBT)

With ROCE of 5.7, it has a Expensive valuation with a 3.6 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 103.76%, its profits have risen by 75.9% ; the PEG ratio of the company is 0.4

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Bafna Pharma. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Bafna Pharma.

103.76%

1.87

55.35%

Sensex

-7.92%

-0.61

13.09%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

16.16%

EBIT Growth (5y)

11.18%

EBIT to Interest (avg)

3.72

Debt to EBITDA (avg)

1.53

Net Debt to Equity (avg)

0.29

Sales to Capital Employed (avg)

1.24

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.34%

ROCE (avg)

8.44%

ROE (avg)

10.80%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.32

EV to EBIT

39.61

EV to EBITDA

24.53

EV to Capital Employed

3.57

EV to Sales

2.60

PEG Ratio

0.43

Dividend Yield

ROCE (Latest)

5.74%

ROE (Latest)

13.09%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

NET SALES(Q)

Highest at Rs 42.24 cr

-1What is not working for the Company

NON-OPERATING INCOME(Q)

is 67.18 % of Profit Before Tax (PBT

Loading Valuation Snapshot...

Here's what is working for Bafna Pharma.

Net Sales - Quarterly

Highest at Rs 42.24 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Here's what is not working for Bafna Pharma.

Non Operating Income - Quarterly

is 67.18 % of Profit Before Tax (PBT)

MOJO Watch

The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT